These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 11442640)

  • 21. Von Willebrand factor-containing factor VIII concentrates and inhibitors in haemophilia A. A critical literature review.
    Franchini M; Lippi G
    Thromb Haemost; 2010 Nov; 104(5):931-40. PubMed ID: 20838738
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inhibitors in young boys with haemophilia.
    Lusher JM
    Baillieres Best Pract Res Clin Haematol; 2000 Sep; 13(3):457-68. PubMed ID: 11030045
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Factor VIII products and inhibitor development in severe hemophilia A.
    Gouw SC; van der Bom JG; Ljung R; Escuriola C; Cid AR; Claeyssens-Donadel S; van Geet C; Kenet G; Mäkipernaa A; Molinari AC; Muntean W; Kobelt R; Rivard G; Santagostino E; Thomas A; van den Berg HM;
    N Engl J Med; 2013 Jan; 368(3):231-9. PubMed ID: 23323899
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prevalence of factor VIII inhibitors in patients with hemophilia A in Brazil.
    Rieger A; Roisenberg I
    Thromb Haemost; 1999 Mar; 81(3):475-6. PubMed ID: 10102489
    [No Abstract]   [Full Text] [Related]  

  • 25. A study of prospective surveillance for inhibitors among persons with haemophilia in the United States.
    Soucie JM; Miller CH; Kelly FM; Payne AB; Creary M; Bockenstedt PL; Kempton CL; Manco-Johnson MJ; Neff AT;
    Haemophilia; 2014 Mar; 20(2):230-7. PubMed ID: 24261612
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inhibitor development in haemophilia according to concentrate. Four-year results from the European HAemophilia Safety Surveillance (EUHASS) project.
    Fischer K; Lassila R; Peyvandi F; Calizzani G; Gatt A; Lambert T; Windyga J; Iorio A; Gilman E; Makris M;
    Thromb Haemost; 2015 May; 113(5):968-75. PubMed ID: 25567324
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inhibitor incidence in haemophilia A under exclusive use of a third-generation recombinant factor VIII concentrate: results of the HEMFIL Cohort Study.
    Jardim LL; van der Bom J; Brommonschenkel CC; Gouw SC; Rezende SM;
    Br J Haematol; 2019 Jul; 186(1):152-155. PubMed ID: 30556277
    [No Abstract]   [Full Text] [Related]  

  • 28. Recombinant factor VIII products and inhibitor development in previously untreated boys with severe hemophilia A.
    Calvez T; Chambost H; Claeyssens-Donadel S; d'Oiron R; Goulet V; Guillet B; Héritier V; Milien V; Rothschild C; Roussel-Robert V; Vinciguerra C; Goudemand J;
    Blood; 2014 Nov; 124(23):3398-408. PubMed ID: 25253771
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Incidence of factor VIII inhibitor development in severe hemophilia A patients treated only with one brand of highly purified plasma-derived concentrate.
    Guérois C; Laurian Y; Rothschild C; Parquet-Gernez A; Duclos AM; Négrier C; Vicariot M; Fimbel B; Fressinaud E; Fiks-Sigaud M
    Thromb Haemost; 1995 Feb; 73(2):215-8. PubMed ID: 7792732
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A Randomized Trial of Factor VIII and Neutralizing Antibodies in Hemophilia A.
    Peyvandi F; Mannucci PM; Garagiola I; El-Beshlawy A; Elalfy M; Ramanan V; Eshghi P; Hanagavadi S; Varadarajan R; Karimi M; Manglani MV; Ross C; Young G; Seth T; Apte S; Nayak DM; Santagostino E; Mancuso ME; Sandoval Gonzalez AC; Mahlangu JN; Bonanad Boix S; Cerqueira M; Ewing NP; Male C; Owaidah T; Soto Arellano V; Kobrinsky NL; Majumdar S; Perez Garrido R; Sachdeva A; Simpson M; Thomas M; Zanon E; Antmen B; Kavakli K; Manco-Johnson MJ; Martinez M; Marzouka E; Mazzucconi MG; Neme D; Palomo Bravo A; Paredes Aguilera R; Prezotti A; Schmitt K; Wicklund BM; Zulfikar B; Rosendaal FR
    N Engl J Med; 2016 May; 374(21):2054-64. PubMed ID: 27223147
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inhibitor development in non-severe haemophilia across Europe.
    Fischer K; Iorio A; Lassila R; Peyvandi F; Calizzani G; Gatt A; Lambert T; Windyga J; Gilman EA; Hollingsworth R; Makris M;
    Thromb Haemost; 2015 Oct; 114(4):670-5. PubMed ID: 26293381
    [TBL] [Abstract][Full Text] [Related]  

  • 32. An analysis of factors affecting the incidence of inhibitor formation in patients with congenital haemophilia in Japan.
    Shirahata A; Fukutake K; Higasa S; Mimaya J; Oka T; Shima M; Takamatsu J; Taki M; Taneichi M; Yoshioka A;
    Haemophilia; 2011 Sep; 17(5):771-6. PubMed ID: 21682824
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Integrated analysis of safety data from 12 clinical interventional studies of plasma- and albumin-free recombinant factor VIII (rAHF-PFM) in haemophilia A.
    Shapiro AD; Schoenig-Diesing C; Silvati-Fidell L; Wong WY; Romanov V
    Haemophilia; 2015 Nov; 21(6):791-8. PubMed ID: 26010678
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Assessment of incidence of inhibitors in patients with haemophilia.
    van der Bom JG; ter Avest P; Van den Berg HM; Psaty BM; Weiss NS
    Haemophilia; 2009 May; 15(3):707-11. PubMed ID: 19432923
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Low factor VIII recovery in haemophilia A patients without inhibitor titre is not due to the presence of anti-factor VIII antibodies undetectable by the Bethesda assay.
    Mondorf W; Klinge J; Luban NL; Bray G; Saenko E; Scandella D;
    Haemophilia; 2001 Jan; 7(1):13-9. PubMed ID: 11136375
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Recombinant factor VIII Fc fusion protein for immune tolerance induction in patients with severe haemophilia A with inhibitors-A retrospective analysis.
    Carcao M; Shapiro A; Staber JM; Hwang N; Druzgal C; Lieuw K; Belletrutti M; Thornburg CD; Ahuja SP; Morales-Arias J; Dumont J; Miyasato G; Tsao E; Jain N; Pipe SW
    Haemophilia; 2018 Mar; 24(2):245-252. PubMed ID: 29436077
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Plasma-derived versus recombinant factor concentrates in PUPs: a never ending debate?
    Berntorp E
    Hamostaseologie; 2017 Jan; 37(1):53-57. PubMed ID: 27878207
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A prospective surveillance study of factor VIII inhibitor development in the Canadian haemophilia A population following the switch to a recombinant factor VIII product formulated with sucrose.
    Rubinger M; Lillicrap D; Rivard GE; Teitel J; Carcao M; Hensman C; Walker I;
    Haemophilia; 2008 Mar; 14(2):281-6. PubMed ID: 18194308
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Genetic background and inhibitors in previously untreated or minimally treated young patients with severe haemophilia A treated with sucrose-formulated recombinant factor VIII.
    Oldenburg J; Ivaskevicius V; Schröder J; Müller CR; Ganguly A
    Thromb Haemost; 2006 May; 95(5):903-5. PubMed ID: 16676088
    [No Abstract]   [Full Text] [Related]  

  • 40. Disappearance of factor VIII:C antibodies in patients with haemophilia A upon frequent administration of factor VIII in intermediate or low dose.
    Van Leeuwen EF; Mauser-Bunschoten EP; Van Dijken PJ; Kok AJ; Sjamsoedin-Visser EJ; Sixma JJ
    Br J Haematol; 1986 Oct; 64(2):291-7. PubMed ID: 3096366
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.